Search Results

US company will extend its microbubble franchise into oncology for French medtech company CarThera - currently running a phase 1/2a study in recurrent glioblastoma with its SonoCloud® system

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), today announced it has entered into a strategic commercial supply agreement with CarThera® for the use of Lantheus’ microbubbles in combination with SonoCloud®, a proprietary implantable device in development for the treatment of recurrent glioblastoma (rGBM)

CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces the appointment of Pascal E. R. Girin as chairman of its board of directors.

KIYATEC, Inc. and CarThera announce today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly aggressive form of brain cancer that afflicts more than 130,000 patients worldwide per year and is characterized by historically poor clinical outcomes.

CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces that it has closed its Series B funding round

CarThera announced the preliminary data of its Phase I/IIa clinical trial (NCT02253212) on ultrasound induced blood-brain barrier (BBB) opening.

Company recently received FDA approval for clinical trial; next generation device, SonoCloud-9, will soon be trialed in US

SonoCloud ultrasound device for glioblastoma patients will be tested for first time at US clinical sites

Good safety profile and encouraging efficacy reported for recurrent glioblastoma patients with disrupted blood-brain barrier

CarTher today announces it has secured approval from the French National Agency for Medicines and Health Products Safety (ANSM) to start a Phase I-II clinical trial of its SonoCloud-9 device in the treatment of recurrent glioblastoma.